NL-OMON51279
Completed
Not Applicable
Study to evaluate the analytical performance of the Virax immune COVID-19 flow cytometry kit - Blood Sampling for Virax Immune COVID*19 Testing
Virax Biolabs Limited0 sites96 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COVID-19 testkit
- Sponsor
- Virax Biolabs Limited
- Enrollment
- 96
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Sex: male or female; females may be of childbearing potential, of
- •nonchildbearing potential, or postmenopausal.
- •2\. Age: 18 to 65 years, inclusive, on the day of consent.
- •3\. Status: healthy subject. Good physical and mental health on the basis of
- •medical history and vital signs, as judged by the Investigator.
- •4\. Females must be nonpregnant; nonpregnancy will be confirmed for all females
- •by a urine pregnancy test.
- •5\. Nonsteroid anti\-inflammatory drugs (ie, ibuprofen, diclofenac, etc.) must
- •have been stopped at least 48 hours prior to admission to the clinical research
- •center (evaluation through questionnaire).
Exclusion Criteria
- •1\. Previous participation in the current study.
- •2\. Employee of ICON or the Sponsor.
- •3\. Having an underlying blood disorder, like leukemia (evaluation through
- •questionnaire).
- •4\. Known to have human anti mouse antibodies (ie, HAMA response; evaluation
- •through questionnaire).
- •5\. Taking immune suppressive medication, or receiving chemotherapy, cytokine or
- •anti\-cytokine therapy, or antithrombotic medication (evaluation through
- •questionnaire).
- •more conditions apply
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
An Investigation to Evaluate the Performance of the Cepheid Xpert® HIV-1 VL XC TestHIV/AIDSPACTR201908919241847Cepheid800
Completed
Not Applicable
Technical Study: Analytical Performance Evaluation of cobas pulse CIM RD005298geen speciale klassen, patienten met en zonder diabetesdiabetes or patient with dysglycemiaNL-OMON49944Roche Diagnostics Operations, Inc600
Suspended
Not Applicable
To compare the performance of RoboICSI with standard existing technique.CTRI/2018/11/016300SPOVUM TECHNOLOGIES PRIVATE LIMITED
Not yet recruiting
Not Applicable
A performance evaluation study for the testing of DNA extracted from either tumor tissue biopsy samples or plasma, using the therascreen® EGFR Plus RGQ PCR Kit, from subjects with Non-Small Cell Lung Cancer, being screened for inclusion in Taiho Oncology, Inc*s Clinical Trial (Protocol No. 10073010).Lung CancerNon Small Cell Lung Cancer10038666NL-OMON56744QIAGE15
Recruiting
Not Applicable
Assessment of the analytical performance of the albumin function test in cancer screeningBreast carcinoma, prostate carcinoma, colorectal carcinoma, lung carcinoma, urinary bladder carcinoma, non-Hodgkin's carcinoma, gastric carcinoma, renal cell carcinoma, endometrial carcinoma, pancreatic carcinomaOrgan diseases of: Lung, Breast, Stomach, Pancreas, Urinary bladder, Kidney, Colon, Blood, Endometrium, Prostate glandDRKS00025249MedInnovation GmbH1,965